Product Images Tadalafil
View Photos of Packaging, Labels & Appearance
- Label - 71610 0903 04
- Aphena - Aphena
- f35596a7-figure-01 - f35596a7 figure 01
- f35596a7-figure-02 - f35596a7 figure 02
- f35596a7-figure-03 - f35596a7 figure 03
- f35596a7-figure-04 - f35596a7 figure 04
- f35596a7-figure-05 - f35596a7 figure 05
- f35596a7-figure-06 - f35596a7 figure 06
- f35596a7-figure-07 - f35596a7 figure 07
- f35596a7-figure-08 - f35596a7 figure 08
- f35596a7-figure-09 - f35596a7 figure 09
Product Label Images
The following 11 images provide visual information about the product associated with Tadalafil NDC 71610-903 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label - 71610 0903 04
Aphena - Aphena
f35596a7-figure-01 - f35596a7 figure 01
f35596a7-figure-02 - f35596a7 figure 02
This is an evaluation chart displaying the standing and supine diastolic blood pressure, as well as the standing and supine systolic blood pressure over time in hours. The text also mentions a note about the blood pressure measurements.*
f35596a7-figure-03 - f35596a7 figure 03
This text contains information about a blood pressure study involving tadalafil (20 mg) and doxazosin (8 mg). The graph appears to show the standing systolic blood pressure change over a certain period, which could potentially illustrate the effects of the medications on blood pressure levels.*
f35596a7-figure-04 - f35596a7 figure 04
The text provides information about a study involving the administration of different doses of tadalafil and doxazosin at different times to evaluate their effects on systolic blood pressure. The study compares the impact of 20 mg tadalafil with 8 mg doxazosin in the morning, 20 mg tadalafil with 8 mg doxazosin in the evening, and a control group receiving a placebo with 8 mg doxazosin. The data seems to be related to monitoring systolic blood pressure changes following the administration of these medications at different times.*
f35596a7-figure-05 - f35596a7 figure 05
f35596a7-figure-06 - f35596a7 figure 06
This text provides information about the change in IPSS Total Score between Tadalafil tablets 5 mg and a placebo over a duration of treatment in weeks. The data indicates a statistically significant difference (p<0.01) between the two treatments.*
f35596a7-figure-07 - f35596a7 figure 07
This text appears to be part of a data set related to a study or clinical trial involving Tadalafil tablets at a dosage of 5 mg. It includes information on the duration of treatment in weeks along with a reference to a placebo group. The data also features a statistical analysis result indicating significance with a p-value of less than 0.001.*
f35596a7-figure-08 - f35596a7 figure 08
This text provides information on the LS Mean Change from Baseline for TadalafilFinasteride and PlaceboFinasteride, along with the Least Squares Treatment Difference. It may be part of a report or clinical study analysis comparing the effects of these treatments.*
f35596a7-figure-09 - f35596a7 figure 09
This text provides information on a study comparing Tadalafil tablets with a placebo over a period of weeks. The significance level is indicated as p<0.01. The data seems to show the impact of treatment duration on the effect of the tablets.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
